Liver and biliary tract cancer trials in Germany

In Germany 56 Also abroad 1316

56 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma
Where
Berlin, Bonn, Chemnitz, Essen, Hamburg, Hanover, Heidelberg, Lübeck, Ulm
Age
18 years and over
People
130
Run by
Universitätsklinikum Hamburg-Eppendorf
See details and how to joinNCT06175845
Phase 3Taking people
A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR) altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308)
Where
Frankfurt am Main, Hamburg, Hanover, Heidelberg, Munich, Reutlingen
Age
18 years and over
People
126 worldwide
Run by
Transthera Sciences (Nanjing) Inc.
See details and how to join2023-505660-11-00
No phaseTaking people
ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer
Where
Münster, Ulm
Age
18 years and over
People
170 worldwide
Run by
Insel Gruppe AG, University Hospital Bern
See details and how to joinNCT06801899
Phase 2Taking people
Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma
Where
Aachen, Bonn, Dresden, Duesseldorf, Essen, Frankfurt am Main, Frankfurt Am Main, Giessen, Goettingen, Hamburg, Jena, Mainz, Mannheim, Munich, Oldenburg, Regensburg, Rostock, Ulm, Wesel
Age
18 years and over
People
40
Run by
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
See details and how to joinNCT07260175 · EU 2024-520219-42-00
Phase 2Taking people
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Where
Berlin, Frankfurt am Main, Heidelberg
Age
8 years and over
People
254 worldwide
Run by
Fore Biotherapeutics
See details and how to joinNCT05503797 · EU 2024-513578-23-00
Phase 1Taking people
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Where
Berlin
Age
18 years and over
People
714 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00
Phase 2Taking people
Randomized Study to Evaluate Melphalan/HDS Treatment Followed by Trifluridine–tipiracil plus Bevacizumab Versus Trifluridine–tipiracil plus Bevacizumab Alone in Metastatic Colorectal Cancer Patients
Where
Hamburg, Hanover, Leipzig
Age
18 years and over
People
35 worldwide
Run by
Delcath Systems Inc.
See details and how to join2024-520356-24-00
No phaseTaking people
DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
Where
Aachen, Halle, Saarbrücken
Age
18 years and over
People
350 worldwide
Run by
Maastricht University Medical Center
See details and how to joinNCT07717437
Phase 2Taking people
Study on the effect of 2 immunotherapy drugs in combination with radioactive glass spheres on the survival in liver cancer
Where
Berlin, Essen, Leipzig, Magdeburg, Munich
Age
18 years and over
People
64 worldwide
Run by
Klinikum der Universitaet Muenchen AöR
See details and how to join2024-515127-11-00
Phase 2/3Not yet taking people in Germany
68Ga-FAPI-46 PET for imaging of gastrointestinal cancers: A prospective interventional single-arm clinical trial (FAPI-PET-GI)
Where
Essen, Muenster
Age
18 years and over
People
150
Run by
Universitaetsklinikum Essen AöR
See details and how to join2023-506030-70-00
Phase 2Taking people
– IKF/AIO-QUINTIS – A Randomized Phase II Trial Evaluating Fruquintinib in Combination with Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer without Active Liver Metastases
Where
Amberg, Augsburg, Bad Saarow, Berlin, Bochum, Chemnitz, Duesseldorf, Essen, Esslingen am Neckar, Frankfurt am Main, Frankfurt Am Main, Halle, Hamburg, Hanover, Herne, Karlsruhe, Leipzig, Munich, Ravensburg, Schweinfurt, Trier, Ulm, Wiesbaden
Age
18 years and over
People
140 worldwide
Run by
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
See details and how to join2024-519929-38-00
Phase 1Taking people
Is CT 01 safe to use alone or combined with Everolimus for inoperable advanced liver cancer?
Where
Heidelberg, Leipzig, Mainz
Age
18 years and over
People
154 worldwide
Run by
Captor Therapeutics S.A.
See details and how to join2024-511435-10-00
No phaseTaking people
Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma
Where
Aachen
Age
18 years to 80 years
People
30
Run by
RWTH Aachen University
See details and how to joinNCT04996914
No phaseTaking people
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Where
Tübingen
Age
18 years and over
People
8,000 worldwide
Run by
UMC Utrecht
See details and how to joinNCT04075305
No phaseTaking people
NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy
Where
Düsseldorf
Age
18 years and over
People
350
Run by
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
See details and how to joinNCT07365930
Phase 4Taking people
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Where
Berlin, Tübingen
Age
18 years to 64 years
People
2,076 worldwide
Run by
Guerbet
See details and how to joinNCT04373564
Phase 4Taking people
A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
Where
Heidelberg, Munich
Age
18 years and over
People
50 worldwide
Run by
Replimune, Inc.
See details and how to joinNCT06887348 · EU 2025-521621-33-00
No phaseTaking people
Prediction of Decompensation and HCC Development in Advanced Chronic Liver Disease
Where
Münster
Age
18 years and over
People
600
Run by
University Hospital Muenster
See details and how to joinNCT06523608
Phase 4Not yet taking people in Germany
HOPE Against Cancer Recurrence in HCC
Where
Essen, Hamburg-Eppendorf, Hanover, Heidelberg, Mainz, München
Age
18 years and over
People
220 worldwide
Run by
Philipp Dutkowski
See details and how to joinNCT06717919
Phase 2Taking people
Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)
Where
Augsburg, Berlin, Cologne, Essen, Heidelberg, Mannheim, Regensburg, Tuebingen, Ulm
Age
18 years and over
People
48
Run by
Michael Dill
See details and how to joinNCT05690048 · EU 2023-506887-15-00
No phaseTaking people
Multiparametric MRI for Characterization of Hepatocellular Carcinoma
Where
Münster
Age
18 years and over
People
128
Run by
University Hospital Muenster
See details and how to joinNCT06999174
No phaseEnrolling by invitation
International Registry of Congenital Portosystemic Shunt (IRCPSS)
Where
Hanover, Munich, Tübingen
Age
1 day and over
People
500 worldwide
Run by
Prof. Valérie Mc Lin
See details and how to joinNCT06041906
No phaseNot yet taking people in Germany
The Dragon PLC Trial (DRAGON-PLC)
Where
Cologne, Dresden, Hanover
Age
18 years and over
People
358 worldwide
Run by
Maastricht University
See details and how to joinNCT06914648
Phase 4Taking people
Treatment of Non-resectable Bile Duct Cancer with Radiofrequency Ablation or Photodynamic Therapy
Where
Aachen, Augsburg, Berlin, Bochum, Bonn, Frankfurt Am Main, Freiburg im Breisgau, Goettingen, Greifswald, Halle (saale), Hanau, Hanover, Leipzig, Ludwigsburg, Mannheim, Marburg, Muenster, Munich, Nuremberg, Stuttgart, Tuebingen
Age
18 years and over
People
258
Run by
University of Leipzig
See details and how to joinNCT05551299 · EU 2022-500107-50-00
No phaseTaking people
Amplitude-modulated Radiofrequency Electromagnetic Field Treatment for Advanced Hepatocellular Carcinoma (Immune-RF)
Where
Berlin
Age
18 years and over
People
36
Run by
Charite University, Berlin, Germany
See details and how to joinNCT06821958